Surrozen, Inc./DE

Chardan NexTech Acquisition 2 Corp, trading under the ticker CHFW and sponsored by Chardan Capital Markets, is a blank-check company that completed its initial public offering in 2021 with a focus on the healthcare and life sciences sector. The SPAC announced a business combination with Surrozen, Inc., a Delaware-incorporated clinical-stage biotechnology company developing Wnt pathway therapies for tissue repair and organ regeneration. An 8-K was filed with the SEC on December 11, 2023, under the combined entity name Surrozen, Inc., reflecting activity tied to the de-SPAC process. The transaction represents a life sciences de-SPAC in the ongoing wave of biotech blank-check mergers. Sign up at SpacDesk for complete filing history, deal timelines, and sponsor intelligence on CHFW and hundreds of other SPACs.